Home/Pipeline/Fc-ANT308

Fc-ANT308

Cancer

Pre-clinicalActive

Key Facts

Indication

Cancer

Phase

Pre-clinical

Status

Active

Company

Cambium Oncology

About Cambium Oncology

Cambium Oncology is pioneering a novel class of immunotherapies targeting the VIP/VPAC axis, an immunosuppressive pathway exploited by cancer cells. Its lead candidate, CAMV-01, is a VIP antagonist designed to re-activate cytotoxic T-cells, with a pipeline that includes small molecules, cell therapies, and long-acting constructs. Founded on IP from Emory University and led by a seasoned team, the company employs a biomarker-driven, combination-focused strategy to de-risk development in a high-value oncology market. Cambium is a private, pre-revenue company advancing its programs through preclinical and early clinical development.

View full company profile

Therapeutic Areas

Oncology

Other Cancer Drugs

Drug	Company	Phase	Status
Not Specified (Oncology Focus)	Narwhal Bio	Pre-clinical	Active
EDM Platform for Genetic Medicine	Coastar Therapeutics	Pre-clinical	Platform Development
CO-1	Caedo Oncology	Pre-clinical	Active R&D
Anti-CD99 monoclonal antibody	Caedo Oncology	Discovery/Pre-clinical	Proprietary antibody identified
Anti-HLA class I monoclonal antibody	Caedo Oncology	Discovery/Pre-clinical	Proprietary antibody identified
Triapine®	Nanopharmaceutics	Clinical	Active
Ammonium Tetrathiomolybdate	Nanopharmaceutics	Clinical	Active
Aza-TdC	Nanopharmaceutics	Clinical	Active
Undisclosed Oncology Program(s)	Cell BioEngines	Phase 1	Active
No-alpha IL-2 Mutein	SarcoMed USA	Pre-clinical	Active
PMIS Therapeutic	NaturemiRI	Preclinical/Clinical (unspecified)	Active
AUM302 (formerly IBL-302)	Inflection Biosciences	Pre-clinical (partnered)	Active